Biomarkers Employed in CheckMate 739 for Patients With MPM
Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.
CheckMate 743 Underscores the Importance of Managing Toxicities in MPM
Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.
CheckMate743 Study Provides Long-Term Data on IO in Mesothelioma
Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.